Genetically engineered pre-microRNA-34a prodrug suppresses orthotopic osteosarcoma xenograft tumor growth via the induction of apoptosis and cell cycle arrest

Osteosarcoma (OS) is the most common primary malignant bone tumor in children, and microRNA-34a (miR-34a) replacement therapy represents a new treatment strategy. This study was to define the effectiveness and safety profiles of a novel bioengineered miR-34a prodrug in orthotopic OS xenograft tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Yong, Tu, Mei-Juan, Wang, Wei-Peng, Qiu, Jing-Xin, Yu, Ai-Xi, Yu, Ai-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4877571/
https://www.ncbi.nlm.nih.gov/pubmed/27216562
http://dx.doi.org/10.1038/srep26611

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4877571/
https://www.ncbi.nlm.nih.gov/pubmed/27216562
http://dx.doi.org/10.1038/srep26611

Ejemplares similares